```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1193 Reported in Senate (RS)]

<DOC>

                                                       Calendar No. 443
117th CONGRESS
  2d Session
                                H. R. 1193

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            December 9, 2021

                                Received

                              May 25, 2022

 Read twice and referred to the Committee on Health, Education, Labor, 
                              and Pensions

                             July 12, 2022

               Reported by Mrs. Murray, with an amendment
 [Strike out all after the enacting clause and insert the part printed 
                               in italic]

_______________________________________________________________________

                                 AN ACT

 
   To amend title IV of the Public Health Service Act to direct the 
Director of the National Institutes of Health, in consultation with the 
Director of the National Heart, Lung, and Blood Institute, to establish 
a program under which the Director of the National Institutes of Health 
 shall support or conduct research on valvular heart disease, and for 
                            other purposes.

 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

<DELETED>SECTION 1. SHORT TITLE.</DELETED>

<DELETED>    This Act may be cited as the ``Cardiovascular Advances in 
Research and Opportunities Legacy Act''.</DELETED>

<DELETED>SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RESEARCH.</DELETED>

<DELETED>    Subpart 2 of part C of title IV of the Public Health 
Service Act (42 U.S.C. 285b et seq.) is amended by inserting after 
section 424C (42 U.S.C. 285b-7c) the following:</DELETED>

<DELETED>``SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE 
              RESEARCH.</DELETED>

<DELETED>    ``(a) In General.--The Director of the National Institutes 
of Health, in consultation with the Director of the Institute, shall 
support or conduct research regarding valvular heart disease.</DELETED>
<DELETED>    ``(b) Support Guidelines.--The distribution of funding 
authorized under subsection (a) may be used to pursue the following 
outcomes:</DELETED>
        <DELETED>    ``(1) Using precision medicine and advanced 
        technological imaging to generate data on individuals with 
        valvular heart disease.</DELETED>
        <DELETED>    ``(2) Identifying and developing a cohort of 
        individuals with valvular heart disease and available 
        data.</DELETED>
        <DELETED>    ``(3) Corroborating data generated through 
        clinical trials to develop a prediction model to distinguish 
        individuals at high risk for sudden cardiac arrest or sudden 
        cardiac death from valvular heart disease.</DELETED>
        <DELETED>    ``(4) For other outcomes needed to acquire 
        necessary data on valvular heart disease.</DELETED>
<DELETED>    ``(c) Mitral Valve Prolapse Workshop.--Not later than one 
year after the date of the enactment of this section, the Director of 
the Institute shall convene a workshop composed of subject matter 
experts and stakeholders to identify research needs and opportunities 
to develop prescriptive guidelines for treatment of individuals with 
mitral valve prolapse.</DELETED>
<DELETED>    ``(d) Authorization of Appropriations.--For the purpose of 
carrying out this section, there is authorized to be appropriated 
$20,000,000 for each of fiscal years 2022 through 2026.''.</DELETED>

<DELETED>SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL AND 
              PREVENTION.</DELETED>

<DELETED>    Part B of title III of the Public Health Service Act (42 
U.S.C. 243 et seq.) is amended by inserting after section 312 the 
following section:</DELETED>

<DELETED>``SEC. 312A. PREVENTION OF SUDDEN CARDIAC DEATH AS A RESULT OF 
              VALVULAR HEART DISEASE.</DELETED>

<DELETED>    ``(a) In General.--The Secretary, acting through the 
Director of the Centers for Disease Control and Prevention, may carry 
out projects to increase education, awareness, or diagnosis of valvular 
heart disease and to reduce the incidence of sudden cardiac death 
caused by valvular heart disease. Such projects may be carried out by 
the Secretary directly or through awards of grants or contracts to 
public or nonprofit private entities. The Secretary may directly (or 
through such awards) provide technical assistance with respect to the 
planning, development, and operation of such projects.</DELETED>
<DELETED>    ``(b) Certain Activities.--Upon availability of applicable 
data, projects carried out under subsection (a) may include--</DELETED>
        <DELETED>    ``(1) continuing the activities at the Division 
        for Heart Disease and Stroke Prevention, including those 
        related to valvular heart disease;</DELETED>
        <DELETED>    ``(2) broadening the awareness of the public 
        concerning the risk factors for, the symptoms of, and the 
        public health consequences of valvular heart disease; 
        and</DELETED>
        <DELETED>    ``(3) enhancing surveillance of out-of-hospital 
        cardiac arrests to improve patient outcomes.</DELETED>
<DELETED>    ``(c) Grant Prioritization.--The Secretary may, in 
awarding grants or entering into contracts pursuant to subsection (a), 
give priority to entities seeking to carry out projects that target 
populations most impacted by valvular heart disease.</DELETED>
<DELETED>    ``(d) Coordination of Activities.--The Secretary shall 
ensure that activities under this section are coordinated, as 
appropriate, with other agencies of the Public Health Service that 
carry out activities regarding valvular heart disease.</DELETED>
<DELETED>    ``(e) Best Practices.--The Secretary, acting through the 
Director of the Centers for Disease Control and Prevention, shall--
</DELETED>
        <DELETED>    ``(1) collect and analyze the findings of research 
        conducted with respect to valvular heart disease; and</DELETED>
        <DELETED>    ``(2) taking into account such findings, publish 
        on the website of the Centers for Disease Control and 
        Prevention best practices for physicians and other health care 
        providers who provide care to individuals with valvular heart 
        disease.''.</DELETED>

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Cardiovascular Advances in Research 
and Opportunities Legacy Act''.

SEC. 2. HHS VALVULAR HEART DISEASE ACTIVITIES.

    (a) In General.--The Secretary of Health and Human Services 
(referred to in this section as the ``Secretary'') shall, as 
appropriate, continue activities related to research, education, and 
awareness of valvular heart diseases.
    (b) NIH Research Related to Valvular Heart Diseases.--
            (1) In general.--The Director of the National Institutes of 
        Health, in consultation with the Director of the National 
        Heart, Lung, and Blood Institute, may support or conduct 
        research regarding valvular heart diseases.
            (2) Support further research.--In order to improve 
        information on, and understanding of, causation and risk 
        factors for valvular heart diseases, research conducted or 
        supported under this subsection for such diseases may include 
        the following:
                    (A) Use of advanced technological imaging and other 
                relevant methods to generate data related to valvular 
                heart diseases.
                    (B) Assessing potential risk factors for sudden 
                cardiac arrest or sudden cardiac death from valvular 
                heart diseases.
                    (C) Other activities, as appropriate, in order to 
                improve the availability of information on, and advance 
                research related to, valvular heart diseases.
            (3) Mitral valve prolapse workshop.--Not later than one 
        year after the date of enactment of this Act, the Director of 
        the National Heart, Lung, and Blood Institute shall, as 
        appropriate, convene a workshop composed of subject matter 
        experts and stakeholders to identify research needs and 
        opportunities to develop recommendations for the identification 
        and treatment of individuals with mitral valve prolapse, 
        including such individuals who may be at risk for sudden 
        cardiac arrest or sudden cardiac death.
    (c) Prevention Activities to Improve Awareness of Sudden Cardiac 
Death as a Result of Valvular Heart Diseases.--
            (1) In general.--The Secretary may carry out activities to 
        increase education and awareness of valvular heart diseases in 
        order to reduce the incidence of sudden cardiac death caused by 
        such diseases. The Secretary may--
                    (A) award grants or contracts to public or 
                nonprofit private entities to carry out activities 
                under this subsection; and
                    (B) may directly, or through grants or contracts, 
                provide technical assistance with respect to such 
                activities.
            (2) Certain activities.--Upon availability of applicable 
        data, projects carried out under paragraph (1) may include--
                    (A) continuing activities at the Centers for 
                Disease Control and Prevention related to valvular 
                heart diseases;
                    (B) improving the awareness of the public 
                concerning any risk factors for, the symptoms of, and 
                the public health impact of, valvular heart diseases; 
                and
                    (C) improving the availability of public health 
                data and information, as appropriate, regarding cardiac 
                arrests related to valvular heart diseases.
            (3) Grant prioritization.--The Secretary may, in awarding 
        grants or entering into contracts pursuant to paragraph (1), 
        give priority to entities seeking to carry out projects for 
        populations most impacted by valvular heart diseases.
            (4) Coordination of activities.--The Secretary shall, as 
        appropriate, ensure that activities under this section are 
        coordinated with other agencies and offices of the Department 
        of Health and Human Services that carry out activities 
        regarding valvular heart diseases.
            (5) Best practices.--The Secretary shall, as applicable and 
        appropriate, identify and disseminate best practices for 
        relevant health care providers related to valvular heart 
        diseases.
    (d) Authorization of Appropriations.--For purposes of carrying out 
this section, there are authorized to be appropriated such sums as may 
be necessary for each of fiscal years 2023 through 2027.
                                                       Calendar No. 443

117th CONGRESS

  2d Session

                               H. R. 1193

_______________________________________________________________________

                                 AN ACT

   To amend title IV of the Public Health Service Act to direct the 
Director of the National Institutes of Health, in consultation with the 
Director of the National Heart, Lung, and Blood Institute, to establish 
a program under which the Director of the National Institutes of Health 
 shall support or conduct research on valvular heart disease, and for 
                            other purposes.

_______________________________________________________________________

                             July 12, 2022

                       Reported with an amendment
```